These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37429701)

  • 1. Intravitreal panitumumab and myopic macular degeneration.
    Bikbov MM; Kazakbaeva GM; Holz FG; Panda-Jonas S; Gilemzianova LI; Khakimov DA; Jonas JB
    Br J Ophthalmol; 2024 May; 108(6):859-864. PubMed ID: 37429701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization.
    Wu TT; Kung YH
    J Ocul Pharmacol Ther; 2012 Apr; 28(2):129-33. PubMed ID: 22066662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epiregulin, epigen and betacellulin antibodies and axial elongation in young guinea pigs with lens-induced myopization.
    Dong L; Zhang RH; Zhou WD; Li YF; Li HY; Wu HT; Shi XH; Jonas JB; Wei WB
    BMC Ophthalmol; 2022 Apr; 22(1):193. PubMed ID: 35477375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
    Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
    Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.
    Ruiz-Moreno JM; Montero JA; Amat-Peral P
    Graefes Arch Clin Exp Ophthalmol; 2011 Apr; 249(4):595-9. PubMed ID: 21234588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.
    Wu L; Hernandez-Bogantes E; Roca JA; Arevalo JF; Barraza K; Lasave AF
    Retina; 2011 Feb; 31(2):298-303. PubMed ID: 21099452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
    Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T;
    Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Wu TT; Kung YH
    Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.
    Mansour AM; Chhablani J; Antonios RS; Yogi R; Younis MH; Dakroub R; Chahine H
    Br J Ophthalmol; 2016 Dec; 100(12):1629-1633. PubMed ID: 27030277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal application of epidermal growth factor in non-exudative age-related macular degeneration.
    Bikbov MM; Khalimov TA; Panda-Jonas S; Jonas JB
    Br J Ophthalmol; 2022 Dec; 106(12):1762-1766. PubMed ID: 34261661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
    Tao Y; Jonas JB
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of myopic macular degeneration severity on treatment outcomes with intravitreal aflibercept in the MYRROR study.
    Cheung CMG; Ohno-Matsui K; Wong TY; Li T; Asmus F; Leal S;
    Acta Ophthalmol; 2019 Aug; 97(5):e729-e735. PubMed ID: 30690902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of epidermal growth factor and its receptor and axial elongation in experimental myopia.
    Dong L; Shi XH; Li YF; Jiang X; Wang YX; Lan YJ; Wu HT; Jonas JB; Wei WB
    FASEB J; 2020 Oct; 34(10):13654-13670. PubMed ID: 32799354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration.
    Zhang M; Zhang J; Yan M; Luo D; Zhu W; Kaiser PK; Yu DC;
    Ophthalmology; 2011 Apr; 118(4):672-8. PubMed ID: 21146224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice.
    Jonas JB; Tao Y; Schlichtenbrede FC
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):467-70. PubMed ID: 21682590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up after multiple intravitreal bevacizumab injections for exudative age-related macular degeneration.
    Tao Y; Libondi T; Jonas JB
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):79-83. PubMed ID: 20148662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity.
    Jonas JB; Tao Y; Rensch F
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):401-5. PubMed ID: 21810019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.